BioPharmSignal logoBioPharmSignal

Biotech News

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.2026-06-25 13:46 ESTFDA / regulatory

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb.

Open original release

Related news

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Biotherapeutics to Present at Upcoming Conference

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Biotherapeutics to Present at Upcoming Conferences

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

IOVAIovance Biotherapeutics, Inc.2026-06-25 13:46 EST

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

View all latest news

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte, or TIL, therapies for solid tumors. The company's story is centered on turning a complex personalized treatment approach into a scalable oncology franchise, with investors watching launch execution, adoption, and the broader...

Recent company news

IOVAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

IOVAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

IOVABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

IOVAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

IOVAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
4.04 USD
Market cap
1.89B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States